SAN DIEGO and CALGARY, AB, April 12, 2023 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, May 5, 2023, at 8:30 a.m. ET to discuss a corporate update and financial results for the first quarter 2023.
Conference Call & Webcast
Date: Friday, May 5, 2023
Time: 8:30 a.m. ET
Dial In – North American Toll-Free: (888) 664-6383
Dial In – International: (416) 764-8650
RapidConnect: to join the conference call without operator assistance, please click here
Conference ID (if needed): 3550-3191
Webcast: please click here
A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for three months. A dial in replay will be available for one week and can be accessed by dialing (888) 390-0541 (North America) or (416) 764-8677 (International) and using replay code: 503-191#.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards registration studies in metastatic breast cancer and pancreatic cancer. For further information, please visit: www.oncolyticsbiotech.com.
Company Contact Jon Patton Director of IR & Communication +1-858-886-7813 This email address is being protected from spambots. You need JavaScript enabled to view it.';document.getElementById('cloakb7c3437890d62b2840912ab8cedbc1ba').innerHTML += ''+addy_textb7c3437890d62b2840912ab8cedbc1ba+'<\/a>'; | Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +1-917-679-9282 This email address is being protected from spambots. You need JavaScript enabled to view it.';document.getElementById('cloak3f127ec7dac27a0a4654004d2c305e5c').innerHTML += ''+addy_text3f127ec7dac27a0a4654004d2c305e5c+'<\/a>'; |
| Last Trade: | US$1.22 |
| Daily Change: | 0.01 0.83 |
| Daily Volume: | 2,818,826 |
| Market Cap: | US$127.510M |
October 28, 2025 September 29, 2025 September 16, 2025 September 08, 2025 September 02, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
